WHO Issues Updated Guideline on Therapeutics for Ebola Virus Disease (iris.who.int)

• WHO released updated evidence-based guideline on EVD therapeutics.
• Recommends monoclonal antibodies Inmazeb and Ebanga as first-line treatments.
• Guideline based on PALM and PREVAIL trial data; critical for outbreak response.

"The World Health Organization has released an updated guideline on therapeutics for Ebola virus disease, providing evidence-based recommendations for the use of monoclonal antibodies and other treatments. The guideline aims to improve clinical management and outbreak response by synthesizing the latest trial data, including results from PALM and other studies. It covers approved drugs such as Inmazeb (atoltivimab/maftivimab/odesivimab) and Ebanga (ansuvimab), as well as investigational agents. The recommendations are critical for healthcare workers in endemic regions and for national Ebola control plans. The guideline aligns with WHO's R&D Blueprint for priority pathogens."